ASH 2023: MPNs

CE / CME

Key Studies in Myeloproliferative Neoplasms: Independent Conference Coverage of ASH 2023

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 06, 2024

Expiration: March 05, 2025

Raajit K. Rampal
Raajit K. Rampal, MD, PhD

Activity

Progress
1 2
Course Completed

Introduction

In this activity, Raajit Rampal, MD, PhD, discusses key findings in myeloproliferative neoplasms presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition.

Please note that the key points discussed in this module are illustrated with thumbnails from accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with myeloproliferative neoplasms do you provide care for in a typical month?

As reported at ASH 2023 for the phase III TRANSFORM-1 trial, each of the following is true regarding treatment with navitoclax plus ruxolitinib vs placebo plus ruxolitinib for patients with JAK inhibitor–naive, higher-risk myelofibrosis (MF), EXCEPT for which one of the following?

Which of the following is an LSD1 inhibitor that demonstrated promising activity for patients with essential thrombocythemia (ET) with inadequate response or intolerance to standard therapy in a phase II study presented at ASH 2023 and is being evaluated in an ongoing phase III trial in this setting?